AXIM's pipeline of intellectual property (IP) protected cannabinoid-based products include:
- MedChew Rx™ - THC/CBD cannabinoid controlled-release functional chewing gum to address pain and muscle spasticity in multiple sclerosis (MS) patients as well as numerous indication extensions based on the proprietary delivery platform
- RENECANN™ - the world's first cannabigerol (CBG)-based skincare product line
- ORAXIMAX™ - the world's first CBG-based oral care product line
- Suppocann™ - a suppository cannabinoid-release product for GI conditions such as IBD, IBS and Crohn's disease
- Ophthocann™ and Cannbleph™ - cannabinoid-based products for reduction of intraocular pressure and for relief of conjunctivitis
LEGAL DISCLOSUREAXIM ® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact:Andrew HardChief Executive OfficerCMW MediaP. firstname.lastname@example.orgCorporate Contact Info:North American Address:18 East 50th Street, 5 FloorNew York, NY 10022+1 844 294 6246European Address:Boelewerf 32, Unit 32987 VD Ridderkerk, The Netherlands+31 10 8209 227